Clinical trials: Botulinum Toxin Injection
- Condition Botulinum Toxin Injection
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Post-Operative Atrial Fibrillation
Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)
This was a multi-center, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of botulinum toxin type A (AGN-151607) injections into the epicardial fat pads, foci of…
- Trial name
- NCT03779841
- Testing
- AGN-151607
- Where
- 32 sites in United States, Austria and 7 more
- Volunteers
- 323 people
- Sponsor
- AbbVie
Wrinkles
Comparison of Two Botulinum Toxins Type A on Forehead Wrinkles
Single-centre, controlled, randomized, evaluator-blinded, bilateral (split-face) comparison study in subjects with moderate to severe forehead wrinkles.
- Trial name
- NCT01014871
- Testing
- Botulinum Toxin Type A - Azzalure, Botulinum Toxin Type A - Vistabel
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Galderma R&D
Episodic Migraine
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (International Classification of Headache Disorders, 2018).
- Trial name
- NCT05028569
- Testing
- BOTOX
- Where
- 133 sites in United States, Canada and 7 more
- Volunteers
- 775 people
- Sponsor
- AbbVie
Upper Facial Lines
A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), lateral canthal lines (LCL), and forehead lines (FHL), are typically treated by selectively weakening specific muscles with small quantities…
- Trial name
- UFL BOND 974 (NCT06218251)
- Testing
- BOTOX
- Where
- 10 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- AbbVie
Platysma Prominence
A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
This is a Phase 3, open-label extension study to evaluate the long-term safety of repeat BOTOX treatments in adult participants with Platysma Prominence.
- Trial name
- NCT05134649
- Testing
- OnabotulinumtoxinA
- Where
- 29 sites in United States, Canada
- Volunteers
- 292 people
- Sponsor
- AbbVie
Chronic Plantar Fasciitis
Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis
This study will investigate the hypothesis that the analgesic effect of a single injection of Dysport (200 MU) induces a significant reduction of symptoms in chronic cases of plantar fasciitis.
- Trial name
- NCT00447876
- Testing
- Botulinum toxin type A
- Where
- 6 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Ipsen
Upper Limb Spasticity
Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity
This is a randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity in Adults After…
- Trial name
- JUNIPER (NCT03821402)
- Testing
- DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U
- Where
- 26 sites in United States
- Volunteers
- 83 people
- Sponsor
- Revance Therapeutics, Inc.
Platysma Prominence
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence.
- Trial name
- NCT04994535
- Testing
- OnabotulinumtoxinA
- Where
- 34 sites in United States, Belgium and 3 more
- Volunteers
- 426 people
- Sponsor
- AbbVie
Arm Spasticity
Comparing Lower-concentration Dysport Treatment Targeted to the Neuromuscular Junction With Current Clinical Practice
The aim of the study was to compare Dysport treatment results (as assessed by Modified Ashworth Scale (MAS) in the elbow joint 4 weeks post treatment) following two treatment techniques: the current clinical practice injection…
- Trial name
- NMJ (NCT01682148)
- Testing
- Botulinum toxin type A
- Where
- 23 sites in Denmark, Finland and 2 more
- Volunteers
- 100 people
- Sponsor
- Ipsen
Platysma Prominence
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence
The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence.
- Trial name
- NCT04949399
- Testing
- OnabotulinumtoxinA
- Where
- 30 sites in United States, Canada
- Volunteers
- 408 people
- Sponsor
- AbbVie
Cervical Dystonia
Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia
Open label study to evaluate the safety and immunogenicity of MYOBLOC (Botulinum Toxin Type B) in adult patients with a clinical diagnosis of Cervical Dystonia (CD).
- Trial name
- NCT00702754
- Testing
- Botulinum Toxin Type B
- Volunteers
- 502 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC